PDF(Pubmed)
Abstract：
UNASSIGNED: Microwave ablation (MWA) is a standard percutaneous local therapy for hepatocellular carcinoma (HCC). Next-generation MWA is reported to create a more spherical ablation zone than radiofrequency ablation (RFA). We compared the ablation zone and aspect ratio of two 2.45 GHz MWA ablation probes; Emprint® (13G) and Mimapro® (17G). We compared the ablation zone to the applied energy after MWA in patients with hepatocellular carcinoma (HCC). Furthermore, we investigated local recurrence.
UNASSIGNED: We included 20 patients with HCC, with an average tumour diameter of 33.2 ± 12.2 mm, who underwent MWA using Emprint®, and 9 patients who underwent MWA using Mimapro® with an average tumour diameter of 31.1 ± 10.5 mm. Both groups underwent the same ablation protocol using the same power settings. The images obtained after MWA showed the treatment ablation zone and aspect ratio, which were measured and compared using three-dimensional image analysis software.
UNASSIGNED: The aspect ratios in the Emprint® and Mimapro® groups were 0.786 ± 0.105 and 0.808 ± 0.122, respectively, with no significant difference (p = 0.604). The ablation time was significantly shorter in the Mimapro® group than in the Emprint® group, and there was no significant difference in the frequency of popping or the ablation volume. There were no significant differences in local recurrence between the two groups.
UNASSIGNED: There was no significant difference in the aspect ratios of the ablation diameter, and the ablation zone was almost spherical in both cases. Mimapro® at 17G was less invasive than Emprint® at 13G.
UNASSIGNED: We included 20 patients with HCC, with an average tumour diameter of 33.2 ± 12.2 mm, who underwent MWA using Emprint®, and 9 patients who underwent MWA using Mimapro® with an average tumour diameter of 31.1 ± 10.5 mm. Both groups underwent the same ablation protocol using the same power settings. The images obtained after MWA showed the treatment ablation zone and aspect ratio, which were measured and compared using three-dimensional image analysis software.
UNASSIGNED: The aspect ratios in the Emprint® and Mimapro® groups were 0.786 ± 0.105 and 0.808 ± 0.122, respectively, with no significant difference (p = 0.604). The ablation time was significantly shorter in the Mimapro® group than in the Emprint® group, and there was no significant difference in the frequency of popping or the ablation volume. There were no significant differences in local recurrence between the two groups.
UNASSIGNED: There was no significant difference in the aspect ratios of the ablation diameter, and the ablation zone was almost spherical in both cases. Mimapro® at 17G was less invasive than Emprint® at 13G.
摘要：
■微波消融（MWA）是肝细胞癌（HCC）的标准经皮局部治疗。据报道，下一代MWA比射频消融（RFA）产生更球形的消融区。我们比较了两个2.45GHzMWA消融探头的消融区和纵横比;Emprint®(13G)和Mimapro®(17G)。我们比较了肝细胞癌（HCC）患者MWA后的消融区与施加的能量。此外，我们调查了局部复发。
■我们纳入了20例肝癌患者，平均肿瘤直径为33.2±12.2mm，他使用Emprint®接受了MWA，和9例使用Mimapro®接受MWA的患者，平均肿瘤直径为31.1±10.5mm。两组均使用相同的功率设置进行相同的消融方案。MWA后获得的图像显示了治疗消融区和纵横比，使用三维图像分析软件进行测量和比较。
■Emprint®和Mimapro®组的纵横比分别为0.786±0.105和0.808±0.122，无显著性差异(p=0.604)。Mimapro®组的消融时间明显短于Emprint®组。爆裂频率或消融体积没有显着差异。两组局部复发差异无统计学意义。
■消融直径的纵横比没有显着差异，在这两种情况下，消融区几乎是球形的。17G的Mimapro®比13G的Emprint®侵入性小。
■我们纳入了20例肝癌患者，平均肿瘤直径为33.2±12.2mm，他使用Emprint®接受了MWA，和9例使用Mimapro®接受MWA的患者，平均肿瘤直径为31.1±10.5mm。两组均使用相同的功率设置进行相同的消融方案。MWA后获得的图像显示了治疗消融区和纵横比，使用三维图像分析软件进行测量和比较。
■Emprint®和Mimapro®组的纵横比分别为0.786±0.105和0.808±0.122，无显著性差异(p=0.604)。Mimapro®组的消融时间明显短于Emprint®组。爆裂频率或消融体积没有显着差异。两组局部复发差异无统计学意义。
■消融直径的纵横比没有显着差异，在这两种情况下，消融区几乎是球形的。17G的Mimapro®比13G的Emprint®侵入性小。
